Dialogue with Chinese authorities on medicine regulation

On October 25, 2019 the Chinese National Medical Product Administration (NMPA) delegation visited EMA. The visit took place in the context of the ongoing EU-China regulatory dialogue on pharmaceuticals.

Topics for discussion between Dr. Shifei Chen, Deputy Commissioner of the Chinese NMPA, Guido Rasi, EMA's Executive Director, Andrzej Rys, Director responsible for Health Systems, Medical Products and Innovation at the European Commission’s Directorate-General for Health and Food Safety included good manufacturing practice (GMP) standards for active pharmaceutical ingredients, good clinical practice (GCP) standards, and the Commission’s strategic approach to pharmaceuticals in the environment.

Discussions were also held around establishing a common training curriculum focused on GMP and GCP standards, in cooperation with other international partners and the World Health Organization (WHO). In addition, EMA introduced the Chinese delegation to EMA’s role and activities in areas like inspection coordination, the evaluation and authorization of medicines, and safety monitoring.

Read more online
Copyright Widler & Schiemann AG 2015. All Rights Reserved. /